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Breast reconstruction is an integral component of 
breast cancer and prophylactic mastectomy manage-
ment.1,2 In the 1980s, prepectoral subcutaneous breast 
reconstruction was plagued with complications, particu-
larly skin flap necrosis that lead to expander exposure 
and loss.3–5 Radovan’s invention of the tissue expander 
and reposition of the expander to the subpectoral plane 
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Background: Prepectoral breast reconstruction is increasingly popular. This study 
compares complications between 2 subpectoral and 1 prepectoral breast recon-
struction technique.
Methods: Between 2008 and 2015, 294 two-staged expander breast reconstructions 
in 213 patients were performed with 1 of 3 surgical techniques: (1) Prepectoral, (2) 
subpectoral with acellular dermal matrix (ADM) sling (“Classic”), or (3) subpec-
toral/subserratus expander placement without ADM (“No ADM”). Demographics, 
comorbidities, radiation therapy, and chemotherapy were assessed for correlation 
with Clavien IIIb score outcomes. Follow-up was a minimum of 6 months.
Results: Surgical cohorts (n = 165 Prepectoral; n = 77 Classic; n = 52 No ADM) had 
comparable demographics except Classic had more cardiac disease (P = 0.03), No ADM 
had higher body mass index (BMI) (P = 0.01), and the Prepectoral group had more 
nipple-sparing mastectomies (P < 0.001). Univariate analysis showed higher expander 
complications with BMI ≥ 40 (P = 0.05), stage 4 breast cancer (P = 0.01), and contralat-
eral prophylactic mastectomy (P = 0.1), whereas implant complications were associated 
with prior history of radiation (P < 0.01). There was more skin necrosis (P = 0.05) and 
overall expander complications (P = 0.01) in the Classic cohort, whereas the No ADM 
group trended toward the lowest expander complications among the 3. Multivariate 
analysis showed no difference in overall expander complication rates between the 3 
groups matching demographics, mastectomy surgery, risks, and surgical technique.
Conclusions: Prepectoral and subpectoral Classic and No ADM breast reconstructions 
demonstrated comparable grade IIIb Clavien score complications. BMI > 40, stage 
4 cancer, and contralateral prophylactic mastectomy were associated with adverse ex-
pander outcomes and a prior history of radiation therapy adversely impacted implant 
outcomes. Ninety-day follow-up for expander and implant complications may be a better 
National Surgical Quality Improvement Program measure. (Plast Reconstr Surg Glob Open 
2017;5:e1433; doi: 10.1097/GOX.0000000000001433; Published online 26 July 2017.)
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revolutionized breast reconstruction.6–8 The subpectoral 
expander method has been the most conventional breast 
reconstruction technique for the past 25 years.9
To our knowledge, there has been no expander-based 
breast reconstruction study comparing a new prepectoral 
technique using stacked acellular dermal matrix (ADM) 
to traditional subpectoral/ADM sling and subpectoral/
seratus/no ADM surgical techniques. This study evaluated 
the outcomes of both stages of reconstruction between 
these 3 surgical techniques.
PATIENTS AND METHODS
A retrospective review of consecutive breast recon-
structions was performed using EPIC electronic medical 
records (Epic Systems Corp., Wis.) at a single institution 
from June 2008 to July 2015. The study was restricted to 
breasts that underwent mastectomy for breast cancer or 
cancer prophylaxis. Excluded breasts were those that un-
derwent immediate single-stage implant reconstruction, 
reconstructions with mesh other than LifeCell Alloderm 
ADM (Branchburg, N.J.), or revisions. Each breast was 
counted once and entered in the study at the time of ex-
pander placement. The specific surgical technique used 
was left to the discretion of the surgeon. Each surgeon per-
formed all 3 techniques during this period. Surgical prod-
ucts were consistent, given the managed care setting. The 
type of mastectomy (skin-sparing, nipple-sparing, or modi-
fied radical) and the final stage of reconstruction (implant 
placement or conversion to free flap) were recorded. Pa-
tients who underwent initial “spacer” expander placement 
for planned adjuvant radiation therapy with subsequent 
autologous reconstruction were included in the expander 
outcomes. The minimum follow-up for both events ranged 
from 6 months to 6 years. The Kaiser Foundation Research 
Institute Institutional Review Board  approved the study.
The following patient demographics were recorded: 
patient age, body mass index (BMI) at the time of the 
initial expander placement (categorized into 5 groups ac-
cording to World Health Organization classification), pres-
ence of diabetes, cardiac disease (requiring medication 
for hypertension, coronary heart disease, or arrhythmia), 
smoking history (current, former), initial cancer stage, 
previous breast surgeries (prior lumpectomy, reduction 
mammoplasty, mastopexy, augmentation mammoplasty), 
radiation therapy (prior history, adjuvant therapy), chemo-
therapy (prior history, neoadjuvant or adjuvant therapy; 
Table 1).10,11 Complications were limited to a grade IIIb Cla-
vien score (i.e., “requiring surgical, endoscopic, or radio-
logical intervention under general anesthesia”) for seroma, 
infection, hematoma, skin and nipple necrosis, expander 
deflation, and expander or implant loss (Table 2).12 It may 
be difficult to identify true surgical-site infections with ADM 
so patients given oral or intravenous antibiotics alone (Cla-
vien type II) were not included.13
The cumulative incidence of postoperative complica-
tions was computed at 30, 90, and 180 days for expander 
and implant placement. Complications for the expander 
and implant were measured separately, each with a sepa-
rate postoperative 6-month follow-up period. Although no 
time stipulation was made for the implant placement, it 
typically occurred 3 months after completion of chemo-
therapy and 6 months after adjuvant radiation therapy.
Surgical Techniques
The 3 surgical procedures were (1) prepectoral tissue 
expander placement over the pectoralis muscle with ADM 
coverage (Prepectoral), (2) subpectoral expander place-
ment with ADM sling as an extension of the pectoralis 
muscle (Classic), (3) subpectoral/subserratus placement 
without ADM (No ADM). Although Sterile Alloderm be-
came available during the study, the same antibiotics were 
used on all breasts. We did not compare outcomes among 
the different generations of Alloderm.
Prepectoral
After mastectomy, an 8 × 16 cm “Thick” ADM (LifeCell 
Alloderm) is sutured in the subcutaneous pocket to the 
medial/parasternal border of the chest wall and along 
the inframammary fold. The lateral most 3–4 cm of the 
8 × 16 cm ADM sheet is removed and sutured to the supe-
rior aspect of the ADM, covering the superior aspect of the 
Natrelle Style 133MV-T tabbed tissue expander (Allergan, 
Santa Barbara, Calif.) (Fig. 1). Bilateral reconstruction uses 
16 × 20 cm, divided in half for each breast, to save costs. The 
partially filled expander is placed under the Alloderm. Ex-
pander tabs are then sutured to the pectoralis muscle and 
chest wall to maintain the expander position. The ADM 
is sutured laterally to create a tight pocket to prevent ex-
pander migration into the axilla. The subcutaneous layer 
is closed by catching the deep dermis and underlying ADM 
with each throw, preventing motion between the mastecto-
my skin flap and ADM with the intent to diminish seroma 
formation. A channel drain is placed over the ADM.
Classic
The leading edge of the pectoral muscle is elevated 
and a subpectoral pocket is fashioned. The lower medial 
origin muscle fibers are released for anatomical expander 
seating. An Alloderm sling is sutured from the leading 
edge of the pectoralis muscle to the inframammary fold 
(over the partially filled expander). The ADM is sutured 
laterally to close the expander pocket.
No ADM
A submuscular pocket is fashioned by elevating the 
pectoralis muscle and a lateral slip of the serratus anterior 
muscle and fascia. A partially filled expander is placed in the 
submuscular pocket. The serratus slip is sutured over the ex-
pander to the lateral pectoral muscle edge. ADM is not used.
Antibiotics were given uniformly throughout the study 
based on the current standard of care at the time of surgery. 
The types of expanders, dressings, postoperative drain man-
agement, and postoperative expansion schedules were simi-
lar for both expanders and implants among surgeons, given 
our group setting. The incisions were dressed with a gauze/
transparent occlusive dressing. The drain was covered with a 
chlorhexidine Biopatch (Ethicon, Johnson & Johnson, New 
Brunswick, N.J.). Drain bulbs were infused daily with 5 cc of 
0.125% Dakin’s hypochlorite solution via needless syringe 
 Bettinger et al. • Prepectoral/Subpectoral Study
3
into the bulb port.14 Drains were removed when output was 
< 30 cc/24 hours × 3 days. Implant choice was based on 
surgeon preference. Fat grafting was performed at implant 
placement to address any contour deficiencies.
STATISTICAL ANALYSIS
First, descriptive statistics were performed to compare 
the demographic characteristics of the 3 surgical cohorts 
Chi-square and t tests were used to evaluate the statistical sig-
nificance of differences within categorical and continuous 
variables, respectively, among the 3 surgical cohorts (Table 1). 
Second, breast complications from either expander or im-
plant placement were evaluated across surgical approaches 
and differences between the 3 approaches were compared us-
ing the chi-square test (Table 2). Third, we performed a uni-
variate logistic regression analysis examining the likelihood of 
developing complications during the expander and implant 
procedure across a number of patient-level and surgical vari-
ables (Table 3). Lastly, a multivariate analysis was performed 
to specifically examine the effect of surgical technique as an 
independent predictor of developing a surgical complica-
tion, while controlling for a number of patient characteristics, 
surgical approaches, and variations in surgeon-specific tech-
niques. Multivariate analysis of implant complications was not 
performed due to low numbers (Table 4).
Statistical analysis occurred at the level of the breast. 
All P values were 2-sided, with a P < 0.05 considered statis-
tically significant. All statistical analyses were performed 
with SAS Studio 3.6 (SAS Institute, Cary, N.C.).
RESULTS
Three hundred thirty-one consecutive breast recon-
structions were performed between June 2008 and July 
2015. Two hundred ninety-four breasts met the inclusion 
Table 1. Patient/Breast Characteristics and Risk Factors
Characteristics Total Classic No ADM Prepectoral P
No. breasts 294 52 77 165  
No. patients 213 40 63 110  
Age 50.95 ± 11.83 51.2 ± 13.71 51.7 ± 11.51 50.9 ± 11.38 0.75
Mean BMI     0.01†
  18.5–24.9 132 (44.90) 22 (42.31) 30 (38.96) 80 (48.48)  
  25–29.9 88 (29.93) 15 (28.85) 24 (31.17) 49 (29.70)  
  30–34.9 44 (14.97) 9 (17.31) 7 (9.09) 28 (16.97)  
  35–39.9 22 (7.48) 6 (11.54) 10 (12.99) 6 (3.64)  
  ≥ 40 8 (2.72) 0 (0.00) 6 (7.79) 2 (1.21)  
Diabetes Mellitus     0.06
  Yes 28 (9.52) 2 (3.85) 12 (15.58) 14 (8.48)  
Cardiac disease     0.03†
  Yes 79 (26.96) 20 (38.46) 24 (31.17) 35 (21.34)  
Smoking history     0.08
  Current 6 (2.04) 3 (5.8) 1 (1.3) 2 (1.2)  
  Former 57 (19.39) 14 (26.9) 14 (18.2) 29 (17.7)  
  None 230 (78.23) 35 (67.3) 62 (80.5) 133 (81.1%)  
Cancer stage     0.16
  Benign/stage 0 139 (47.27) 24 (8.16) 30 (10.2) 85 (28.9)  
  Stage 1 72 (24.48) 15 (28.8) 21 (27.3) 36 (21.8)  
  Stage 2–3 61 (20.74) 12 (4.1) 25 (8.5) 42 (14.3)  
  Stage 4 4 (1.36) 1 (1.9) 1 (1.3) 2 (1.2)  
Previous breast surgery     0.07
  Yes 28 (9.5) 2 (3.8) 12 (15.6) 14 (8.5)  
Chemo     0.20
  Adjuvant 121 (41.16) 25 (48.08) 25 (32.47) 71 (43.03)  
  Prior history 18 (6.12) 4 (7.69) 7 (9.09) 7 (4.24)  
  Neoadjuvant 29 (9.86) 4 (7.69) 5 (6.49) 20 (12.12)  
Radiation     0.86
  Adjuvant 41 (13.95) 8 (15.38) 10 (12.99) 23 (13.94)  
  Prior history 22 (7.48) 2 (3.85) 6 (7.79) 14 (8.48)  
Mastectomy type* (n = 291)     
  Skin-sparing 214 (73.5) 42 (80.8) 55 (71.4) 117 (70.9) 0.01†
  Nipple-sparing 50 (17.1) 6 (11.54) 2 (2.60) 42 (25.45) < 0.001†
  Modified radical 27 (3.4) 4 (7.7) 17 (23) 6 (3.6) < 0.01†
Surgery indication      
  Prophylactic (CL) 101 (34.35) 17 (32.69) 22 (28.57) 62 (37.58) 0.37
  Prophylactic (BL) 31 (10.54) 6 (11.5) 9 (11.6) 16 (9.67)  
Timing      
  Immediate 269 (91.5) 50 (96.2) 55 (71.4) 164 (99.4) < 0.001†
Conversion to flap at second 
stage
9 (3.1) 3 (5.8) 1 (1.3) 5 (3.0) 0.35
Completion of reconstruction 235 (79.9) 41 (78.8) 67 (87) 127 (77) 0.17
Previous breast surgery = formal lumpectomy, breast reduction, breast augmentation, mastopexy (does not include open breast biopsy); conversion to flap at 
second stage: autologous flap reconstruction occurred at the second stage of reconstruction due to either complication or patient choice instead of implant. Any 
expander complication recorded.
*Three breasts had unknown mastectomy type.
†Values are statistically significant.
BL, bilateral prophylactic mastectomy; BMI, body mass index; CL, contralateral prophylactic mastectomy.
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criteria, which consisted of 165 Prepectoral, 77 Classic, 
and 52 No ADM reconstructions. The mean age for all 
groups was 50.95 (Table 1). Demographics were similar 
except the Classic cohort had higher rates of cardiac dis-
ease (P = 0.03) and a trend toward higher smoking rates 
(current and former; P = 0.08). BMI ≥ 35 was higher in the 
Classic group and the No ADM group (P = 0.01). A trend 
toward increased rates of diabetes in the No ADM group 
was also noted (P = 0.06).
Among mastectomy techniques, there were more nipple-
sparing mastectomies in the Prepectoral group (P < 0.001) 
and more skin-sparing mastectomies in the Classic and No 
ADM groups (P = 0.01). Unfortunately, we were not able 
to identify information for mastectomy type for 3 patients, 
and these were excluded from analysis. There were similar 
rates of prophylactic mastectomy in the 3 groups. No differ-
ence was noted between the 3 groups in the final stage of 
reconstruction (i.e., successful completion) or second-stage 
conversion rate to autologous flap reconstruction (Table 1).
Multiple complication variables were often seen in the 
same patient, causing higher complication numbers. For 
instance, an infected breast with necrotic skin flaps might 
be associated with loss of expander, recording 3 complica-
tions in a single breast. All complications were recorded in 
a “genomic-type format” to show this interrelationship. No 
pattern emerged with any of the surgical cohorts.
We looked at complications per patient as well as per 
breast. However, we found that complications were better 
examined per breast as each breast had its own individual 
risk factors. For example, a reconstructed breast may un-
dergo radiation (higher risk), whereas the other breast 
does not but still undergoes prophylactic mastectomy 
(lower risk).
Expander Complications
The overall infection rate was 6.80% for expander 
surgery. The difference in infection among the 3 surgical 
Table 2.  Complications after Expander and Implant Surgery
Complications/breast Total Classic No ADM Prepectoral P
Expander 294  52 77 165  
  No. breasts      
  Any expander complications      
   Yes 40 (13.61)  13 (25.00) 5 (6.49) 22 (13.33) 0.01†
  Loss      
   Expander 25 (8.50) 8 (15.38) 2 (2.60) 14 (8.48) 0.09
   Deflation 2 (0.68) 0 (0.00) 0 (0.00) 2 (0.68)  
  Seroma      
   Yes 13 (4.42) 3 (5.77) 5 (6.49) 5 (3.03) 0.44
  Hematoma      
   Yes 3 (1.02) 1 (1.92) 0 (0.00) 2 (1.21) 0.40
  Infection      
   Yes 20 (6.80) 6 (11.54) 3 (3.90) 11 (6.67) 0.37
  Skin necrosis      
   Yes 15 (5.10) 7 (13.46) 2 (2.60) 6 (3.64) 0.05†
  Nipple necrosis      
   Yes 5 (1.70) 2 (3.85) 0 (0.00) 3 (1.82) 0.25
Implant Total 38 65 119  
  No. breasts 222*     
  Any implant complications      
   Yes 11 (4.95) 1 (2.63) 3 (4.62) 7 (5.88) 0.72
   Loss      
   Implant 7 (3.15) 1 (2.63) 1 (1.54) 5 (4.20) 0.21
  Seroma      
   Yes 6 (2.70) 0 (0.00) 1 (1.54) 5 (4.20) 0.22
  Hematoma      
  Yes 1 (1.45) 0 (0.00) 1 (1.54) 0 (0.00) 0.37
  Infection      
   Yes 5 (2.25) 0 (0.00) 1 (1.54) 4 (3.36) 0.11
  Skin necrosis      
   Yes 5 (2.25) 1 (2.63) 1 (1.54) 3 (2.52) 0.29
  Nipple necrosis      
   Yes 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) —
*Total number of breast reconstructions that underwent implant placement by study completion.
†Values are statistically significant.
Fig. 1. Prepectoral reconstruction technique: Stacked aDM
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Table 3. Univariate Logistic Regression Analysis Predicting Development of Expander and Implant Complications
Characteristics Expander No. Rate (%) OR (95% CI) P Implant No. Rate (%) OR (95% CI) P
Technique         
  Classic 13 25.00 1 (Reference) — 1 2.63 1 (Reference) —
  No ADM 5 6.49 0.21 (0.07–0.63) 0.01† 3 4.62 0.56 (0.06–5.57) 0.84
  Prepectoral 22 13.33 0.46 (0.21–1.00) 0.98 7 5.88 0.43 (0.05–3.63) 0.44
Age* 51.38 12.28 1.004 (0.976–1.032) 0.80 50.45 10.83 1.00 (0.95–1.05) 0.99
BMI         
  18.5–24.9 15 11.36 1 (Reference) — 2 1.52 1 (Reference) —
  25–29.9 10 11.36 1.00 (0.43–2.34) 0.43 4 4.55 3.03 (0.54–17.02) 0.47
  30–34.9 11 25.00 2.600 (1.09–6.20) 0.09 2 4.55 3.57 (0.48–26.50) 0.74
  35–39.9 1 4.55 0.37 (0.05–2.96) 0.12 2 9.09 6.68 (0.87–50.95) 0.56
  ≥ 40 3 37.50 4.680 (1.01–21.59) 0.05† 1 12.50 25.00 (1.55–402.46) 0.09
Diabetes         
  No 35 13.16 1 (Reference) —  4.43 1 (Reference) —
  Yes 5 17.86 1.42 (0.51–3.97) 0.51  10.53 2.54 (0.51–12.69) 0.26
Cardiac disease         
  No 26 12.15 1 (Reference) — 6 3.47 1 (Reference) —
  Yes 14 17.72 1.54 (0.76–3.13) 0.23 5 10.20 3.16 (0.92–10.85) 0.07
Smoking         
  No 32 13.85 1 (Reference) — 10 5.75 1 (Reference) —
  Former or current 8 12.90 0.91 (0.40–2.09) 0.83 1 2.08 0.35 (0.04–2.80) 0.32
Cancer stage         
  Benign/stage 0 19 15.20 1 (Reference) — 6 4.80 1 (Reference) —
  Stage 1 12 19.67 1.366 (0.62–3.04) 0.16 3 4.92 1.53 (0.362–6.49) 0.94
  Stage 2–3 5 22.73 1.641 (0.54–4.98) 0.14 0 0.00 — 0.95
  Stage 4 4 4.76 0.279 (0.09–0.85) 0.01† 2 2.38 0.48 (0.09–2.45) 0.96
Previous breast surgery         
  No 32 12.75 1 (Reference) — 9 4.76 1 (Reference) —
  Yes 8 18.60 1.60 (0.68–3.75) 0.28 2 6.06 1.29 (0.27–6.26) 0.75
Chemo         
  None 15 11.90 1 (Reference) — 4 3.70 1 (Reference) —
  Adjuvant 15 12.40 1.058 (0.49–2.27) 0.36 6 6.98 1.96 (0.53–7.17) 0.95
  Prior history 3 16.67 1.46 (0.38–5.67) 0.90 1 9.09 2.58 (0.26–25.31) 0.94
  Neoadjuvant 7 24.14 2.33 (0.85–6.38) 0.16 0 0.00 — —
Radiation         
  None 27 11.69 1 (Reference) — 6 3.31 1 (Reference) —
  Adjuvant 8 19.51 1.81 (0.76–4.33) 0.72 1 3.57 1.08 (0.13–9.32) 0.24
  Prior history 5 22.73 2.34 (0.79–6.90) 0.32 4 30.77 12.96 (3.10–54.25) < 0.01†
Stage of reconstruction         
  No expander/implant 12 57.14 1 (Reference) — 3 27.27 1 (Reference) —
  Expander in place 8 21.05 0.200 (0.06–0.64) 0.55 0 0.00 — —
  Second stage finished 20 8.51 0.070 (0.03–0.19) < 0.01† 8 3.70 0.03 (0.01–0.18) 0.99
Skin-sparing         
  No 9 13.85 1 (Reference) — 4 8.70 1 (Reference) —
  Yes 31 13.54 0.99 (0.45–2.20) 0.98 7 3.98 0.44 (0.12–1.56) 0.20
Nipple-sparing         
  No 33 13.52 1 (Reference) — 9 4.81 1 (Reference) —
  Yes 7 14.00 1.03 (0.43–2.47) 0.95 2 5.71 1.20 (0.25–5.80) 0.82
Contralateral prophylactic 
mastectomy
        
  No 34 17.62 1 (Reference) — 7 4.93 1 (Reference) —
  Yes 6 5.94 0.30 (0.12–0.74) 0.01† 4 5.00 1.01 (0.29–3.58) 0.98
*For continuous variable age, we report the mean age of patients who developed complications along with the SD. Chemotherapy and radiation: prior history, 
before, and not related to current surgical intervention, that is, related to previous diagnosis of breast cancer.
†Values are statistically significant.
BMI, body mass index; CI, confidence interval; OR, odds ratio.










Adjusted* Risk  
Ratio, (95% CI) P
Classic 13 25.00 1 (Reference)  1 (Reference)  
No ADM 5 6.49 0.21 (0.07–0.63) 0.02† 0.12 (0.02–0.72) 0.10
Prepectoral 22 13.33 0.46 (0.21–1.00) NS 0.25 (0.06–1.00) NS
*N = 291, adjusted for 3 unknown variables for mastectomy type and for patient characteristics (including age, BMI, cancer stage, cardiac disease, smoking status, 
diabetes, chemotherapy, radiation and previous breast surgery, timing) + considerations in surgical approach [including mastectomy type (skin-sparing, nipple-
sparing, and contralateral prophylactic mastectomy)] and stage of reconstruction + effects attributable to surgeon variation. Unknown breast reconstructions 
(n = 3) were excluded in this analysis since the type of mastectomy was unknown.
†Values are statistically significant.
CI, confidence interval; NS, not significant.
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groups was not statistically significant, and the incidence 
of seroma was similar among all 3 groups (P = 0.44).
The Classic cohort had significantly more skin necrosis 
(P = 0.05) and overall expander complications (P = 0.01) 
than the other 2 surgical techniques (Fig. 2); there were 
more current and former smokers in the Classic group (P = 
0.08). There was no statistical difference in nipple necrosis 
in nipple-sparing mastectomy among the surgical groups 
but the numbers were low (Table 2). With univariate analy-
sis, there was a trend toward a higher loss of expander in 
the Classic group (P = 0.09). However, when placed in a 
multivariate analysis, this trend disappeared, and all 3 tech-
niques had similar expander complication rates (Table 4).
On the other hand, the No ADM technique had the 
least number of expander complications among the 
3 groups (P = 0.02) in a univariate analysis. Although a 
trend persisted when analyzed in a multivariate fashion, 
the statistical significance was lost (P = 0.12).
Implant Complications
The overall infection rate for implant surgery was 
2.25% and the seroma formation rate was 2.70%. There 
was no statistically significant difference in implant com-
plications between the Classic, Prepectoral, and No ADM 
surgical groups using univariate analysis (Table 2). The 
number of implant complications was too low to perform 
multivariate analysis.
Risk Factors
Of the 294 breasts entered in the study, 13.6% (n = 40) 
had complications related to the expander, whereas 3.7% 
(n = 11) were implant-related. A history of radiation before 
initial expander placement appeared to show a nonsig-
nificant increase in expander complications but a strik-
ing increase (30%) in implant complications (P < 0.01; 
Table 3). Of the total number of implant complications, 
almost half (5/11 = 45%) were associated with either ad-
juvant or preexpander radiation. Although the numbers 
were low, implant loss in the Prepectoral group was seen 
either with radiation (3/5 = 60%) or cardiac disease (2/5 
= 40%). Chemotherapy, whether neoadjuvant, adjuvant, 
or a prior history, did not increase the risk of complica-
tions for  expander or implant surgery (Table 3).
With univariate analysis, there was a significantly high-
er rate of overall expander complications for patients with 
a BMI of 40 or greater (P = 0.05) in all surgical cohorts. 
There was no difference in outcome complications with 
both expander and implant placement among patients 
with diabetes (P = 0.26). Despite the higher rate of car-
diac disease in the Classic group, univariate analysis did 
not reach significance to indicate that cardiac disease was 
associated with higher rates of complications; however, 
there was a trend toward significance that may suggest an 
association if the power of the test is increased (P = 0.07).
Previous breast surgery did not affect outcomes among 
the 3 surgical cohorts. There was no statistical difference 
in outcomes with respect to mastectomy type and unilater-
al prophylactic mastectomy between the 3 surgical cohorts 
(Table 3). Bilateral prophylactic mastectomy reconstruc-
tions had too few complication numbers to perform this 
analysis.
DISCUSSION
With increasing prophylactic breast reconstruction 
and nipple-sparing mastectomy for both cancer and can-
cer prophylaxis, women are demanding a breast compa-
rable with their natural breast, with less discomfort, less 
contour deformity with minimal surgical sequela, scar-
ring, and downtime. A renewed interest has been seen 
with suprapectoral reconstruction (thick mastectomy 
flaps without ADM) and prepectoral reconstruction tech-
niques that now use ADM to avoid the dynamic deformity 
sometimes seen with subpectoral reconstruction.15–20 A 
“bioengineered” biodimensional subpectoral breast re-
construction including ADM both at mastectomy and im-
plant surgery, an anatomical/form-stable implant, and fat 
grafting aims to recreate a better breast.21
Fewer complications have been noted in reconstruc-
tions without ADM.22,23 Adverse outcomes with ADM have 
been inconsistent in the literature but generally associated 
higher rates of seroma, infection, skin necrosis, and in-
creased loss of expander are seen.24–32 In this study, seroma 
formation requiring surgical intervention was 4.42% over-
all for expanders and 2.70% for implants. We did not find 
a statistical difference in seroma or infection rates when 
comparing techniques that did and did not use ADM.
Increased complication rates have been noted in pa-
tients with diabetes, hypertension, BMI > 30, and contralat-
eral prophylactic mastectomy.33–37 In this study, diabetes did 
not cause a higher complication rate among the 3 groups. 
Univariate analysis showed statistically higher expander 
complications with BMI ≥ 40 (P = 0.05) and stage 4 cancer 
but not in final implant placement. We also found recon-
structed breasts with a contralateral prophylactic mastec-
tomy had more overall expander complications (P = 0.01).
The Classic cohort had a statistically greater inci-
dence of cardiac disease (P = 0.03), more skin necrosis 
Fig. 2. expander complications at 180 days. Percentage of recon-
struction complications.
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(P = 0.05), and a higher overall expander complication 
rate (P = 0.01). More skin necrosis was found with the 
Classic cohort in which surgical release of the pectoralis 
lower medial border is usually performed for anatomical 
seating of the expander but not performed in Prepectoral 
or No ADM. Like others, we observed “window-shading” 
of scarred, anatomically foreshortened pectoralis muscles 
intraoperatively for surgical complications in the Classic 
cohort.16 This window-shading may contribute to poorer 
chest skin/pericapsular vascularity. In contrast, in No 
ADM, the pectoralis lateral margin is anchored inferi-
orly by the serratus slip, counteracting window-shading. 
Prepectoral reconstruction involves no disruption of the 
muscle origin or division of the underlying perforators.
An increase in nipple necrosis has been seen with neo-
adjuvant and adjuvant chemotherapy with suprapectoral 
reconstruction and nipple-sparing mastectomy, but we did 
not see this in our study (Table 3).38 Timing of radiation 
is known to influence both expander and implant out-
comes.39,40 We found no statistical increase in complica-
tions with adjuvant radiation therapy alone, but there was 
a 10-fold increase in implant complication rate with prior 
history of radiation (i.e., before expander).
We find that expander/implant complications are not 
always captured by the 30-day National Surgical Quality 
Improvement Program (NSQIP) benchmark.41,42 Peripros-
thetic joint literature divides complications into “early” 
at 90 days and “late” at 6 months or later.43,44 We tracked 
our complications at 30, 90, and 180 days postoperatively. 
All our complications occurred within 90 days for both 
expander and implant placement. Our study outcomes 
would lead us to conclude that 90 days “early” follow-up is 
more accurate than existing 30-day NSQIP measures and 
a “late” follow-up of 180 days is appropriate.
The results of our study seem to indicate that for those 
breasts with increased risk, subpectoral/serratus recon-
struction results in fewer complications. Subpectoral/
ADM sling reconstruction should be more closely studied 
for the vascular impact of window-shading particularly in 
the setting of cardiac disease and a history of smoking. 
Prepectoral breast reconstruction appears to be impacted 
by radiation before implant surgery, similar to subpectoral 
techniques. Contralateral prophylactic mastectomy recon-
struction carries greater overall complications and should 
be shared with patients in their decision making.
Strengths and Limitations
Study strengths include a comparative study designed 
to evaluate major complication outcomes requiring sur-
gical intervention with the prepectoral breast reconstruc-
tion technique compared with traditional methods of 
subpectoral breast reconstruction with 30, 90, and 180-day 
follow-up of both expander and implant outcomes.
Study limitations include small cohorts in a retrospec-
tive review at a single institution. Randomization to a sur-
gical technique would not be ethical. We did not evaluate 
“phase 2” efficacy for capsular contracture nor contour 
deformity. The Pusic’s Breast Q score questionnaire could 
be valuable for patient satisfaction.45 Cost analysis would 
be important as prepectoral reconstruction uses the larg-
est ADM sheet, whereas No ADM uses none. We did not 
perform a power analysis, given a potential risk of type II 
error. The results of this study should be interpreted in 
the context of relatively low numbers. Further studies with 
larger numbers are warranted.
CONCLUSIONS
All 3 surgical cohorts had comparable Clavien IIIb 
score outcomes with the No ADM trending to the lowest 
complication rate. BMI ≥ 40, stage 4 cancer, and contralat-
eral prophylactic mastectomy were associated with adverse 
expander outcomes. Prior radiation therapy caused an 
overall 10-fold increase in implant loss among the 3 surgi-
cal groups. Diabetes, prior breast surgery, type of mastec-
tomy, and chemotherapy played no role in complications 
in our study. We did not see a higher rate of seroma in the 
cohorts with ADM techniques. A higher rate of skin necro-
sis in the Classic group may have been related to higher 
incidence of cardiac disease or the impact of window-
shading of the pectoralis muscle. NSQIP may consider 
tracking 90-day outcomes for expander/implant surgery, 
rather than 30 days. Larger, prospective studies including 
aesthetic outcomes would be beneficial.
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